{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:05:36Z","timestamp":1756339536975,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,3,11]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>A woman in her 70s who was being followed up for neovascular age-related macular degeneration (nAMD) in both eyes for 2\u2009years with recalcitrant choroidal neovascularisation (CNV) and had an episode of acute endophthalmitis in one eye was identified. After treatment of postinjection culture-negative right eye (RE) endophthalmitis with intravitreal vancomycin and tazobactam, the patient had complete regression of treatment-resistant CNV in RE to date with postinfection follow-up of 2 years. In contrast, the fellow eye continued showing activity in the choroidal neovascular membrane that required antivascular endothelial growth factor injections on a pro re nata basis to date. Prolonged regression of nAMD for 3\u2009years in the affected eye and continued activity in the fellow eye support the hypothesis that inflammation accompanying endophthalmitis or the drugs used for the treatment can have a role in the regression of nAMD.<\/jats:p>","DOI":"10.1136\/bcr-2021-244771","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T03:58:15Z","timestamp":1666583895000},"page":"e244771","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Bilateral neovascular age-related macular degeneration: unilateral regression following endophthalmitis with persistent activity in the fellow eye"],"prefix":"10.1136","volume":"15","author":[{"given":"Sandhya","family":"Gaur","sequence":"first","affiliation":[{"name":"Retina Services, Eye-Q Superspecialty Eye Hospitals, Gurugram, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deependra Vikram","family":"Singh","sequence":"additional","affiliation":[{"name":"Retina Services, Eye-Q Superspecialty Eye Hospitals, Gurugram, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-6377","authenticated-orcid":false,"given":"Raja Rami","family":"Reddy","sequence":"additional","affiliation":[{"name":"Retina Services, Neo Retina Eye Institute, Nampalli, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Retina Services, Eye-Q Superspecialty Eye Hospitals, Gurugram, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2025082710040480000_15.3.e244771.1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the trend study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"2025082710040480000_15.3.e244771.2","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-Year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"doi-asserted-by":"publisher","key":"2025082710040480000_15.3.e244771.3","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"2025082710040480000_15.3.e244771.4","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2415-14-76","article-title":"Spectral domain optical coherence tomography in patients after successful management of postoperative endophthalmitis following cataract surgery by pars plana vitrectomy","volume":"14","author":"Maneschg","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"2025082710040480000_15.3.e244771.5","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/2474126420914282","article-title":"Quiescent neovascular age-related macular degeneration after endophthalmitis","volume":"4","author":"Robbins","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"2025082710040480000_15.3.e244771.6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ICB.0000000000000352","article-title":"Resolution of treatment-resistant subretinal fluid in a patient with exudative age-related macular degeneration following endophthalmitis","volume":"11","author":"Kally","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"2025082710040480000_15.3.e244771.7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/ICB.0b013e3181d426e8","article-title":"Regression of choroidal neovascularization after vitrectomy for postinjection endophthalmitis","volume":"4","author":"Emoto","year":"2010","journal-title":"Retin Cases Brief Rep"},{"unstructured":"Kokame GT , Yannuzzi NA , Shantha JG . Involution of neovascular age-related macular degeneration after endophthalmitis, 2019.","key":"2025082710040480000_15.3.e244771.8"},{"doi-asserted-by":"publisher","key":"2025082710040480000_15.3.e244771.9","DOI":"10.1073\/pnas.1814014116"},{"key":"2025082710040480000_15.3.e244771.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205292","article-title":"Elevated cytokine levels in vitreous as biomarkers of disease severity in infectious endophthalmitis","volume":"13","author":"Deshmukh","year":"2018","journal-title":"PLoS One"},{"key":"2025082710040480000_15.3.e244771.11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2017.06.015","article-title":"Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration","volume":"181","author":"Kawashima","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"2025082710040480000_15.3.e244771.12","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"doi-asserted-by":"publisher","key":"2025082710040480000_15.3.e244771.13","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"2025082710040480000_15.3.e244771.14","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/IAE.0000000000002998","article-title":"Clinical outcomes and treatment course of eyes with neovascular age-related macular degeneration following the development of endophthalmitis","volume":"41","author":"Koulisis","year":"2021","journal-title":"Retina"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-244771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:04:13Z","timestamp":1756314253000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-244771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,24]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bcr-2021-244771"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-244771","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}